Favorable News Coverage Somewhat Unlikely to Impact PhotoMedex (PHMD) Share Price
Media stories about PhotoMedex (NASDAQ:PHMD) have been trending positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. PhotoMedex earned a news sentiment score of 0.27 on Accern’s scale. Accern also assigned news headlines about the medical equipment provider an impact score of 44.6983424866219 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
PhotoMedex (NASDAQ:PHMD) remained flat at $1.14 during mid-day trading on Wednesday. The company’s stock had a trading volume of 21,621 shares. PhotoMedex has a 12 month low of $0.71 and a 12 month high of $5.60. The company’s market cap is $4.83 million. The firm’s 50-day moving average is $0.97 and its 200-day moving average is $1.51.
Separately, ValuEngine upgraded shares of PhotoMedex from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd.
PhotoMedex Company Profile
PhotoMedex, Inc is a global health products and services company providing integrated disease management and solutions to dermatologists, professional aestheticians and consumers. The Company provides products and services that address skin diseases and conditions, including acne and photo damage. The Company operates through three business segments: Consumer segment, Physician Recurring segment and Professional segment.
Receive News & Ratings for PhotoMedex Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhotoMedex Inc and related companies with MarketBeat.com's FREE daily email newsletter.